Eagle Pharmaceuticals, Inc. is a US-based pharmaceutical company with a medium risk ESG score of 23.6. Specializing in injectable products for critical care, orphan diseases, and oncology, the company offers a portfolio of four approved products. Also, Eagle Pharmaceuticals has several product candidates awaiting approval from the FDA.